IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8999966 B1

PDFFull Text
Date of Patent:
Apr. 07, 2015

Filed:

Oct. 24, 2011

Compounds that are erk inhibitors

Applicants:

Sobhana Babu Boga, Scotch Plains, NJ (US);

Joseph M. Kelly, Parlin, NJ (US);

Hugh Y. Zhu, Warren, NJ (US);

Abdul-basit Alhassan, Scotch Plains, NJ (US);

Xin Yao, Westfield, NJ (US);

Xiaolei Gao, Bridgewater, NJ (US);

James J-s Wang, Westfield, NJ (US);

Jagdish A. Desai, Monroe Township, NJ (US);

Subrahmanyam Gudipati, Edison, NJ (US);

Sie-mun Lo, Springfield, VA (US);

Liang Zhu, Waltham, MA (US);

Alan B. Cooper, West Caldwell, NJ (US);

Yongqi Deng, Newton, MA (US);

Gerald W. Shipps, Jr., Stoneham, MA (US);

Inventors:

Sobhana Babu Boga, Scotch Plains, NJ (US);

Joseph M. Kelly, Parlin, NJ (US);

Hugh Y. Zhu, Warren, NJ (US);

Abdul-Basit Alhassan, Scotch Plains, NJ (US);

Xin Yao, Westfield, NJ (US);

Xiaolei Gao, Bridgewater, NJ (US);

James J-S Wang, Westfield, NJ (US);

Jagdish A. Desai, Monroe Township, NJ (US);

Subrahmanyam Gudipati, Edison, NJ (US);

Sie-Mun Lo, Springfield, VA (US);

Liang Zhu, Waltham, MA (US);

Alan B. Cooper, West Caldwell, NJ (US);

Yongqi Deng, Newton, MA (US);

Gerald W. Shipps, Jr., Stoneham, MA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Richard S. Parr

Laura M. Ginkel

Primary Examiner:

Samantha Shterengarts

Int. Cl.
CPC ...
A61K 31/397 (2006.01); A61K 31/5377 (2006.01); A61K 31/506 (2006.01); A61K 31/4545 (2006.01); A61K 31/454 (2006.01); A61K 31/4523 (2006.01); A61K 31/4427 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); C07D 413/14 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 221/00 (2006.01); C07D 221/02 (2006.01); C07D 211/80 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); A61K 31/444 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01);
Abstract

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

Find Patent Forward Citations

Loading…